<p>/PRNewswire/ -- 国家肾脏基金会（NKF）今天宣布，其创新基金已投资于 Biohope，这是一家开发精准诊断技术的生物技术公司，旨在为肾脏移植接受者以及自身免疫和炎症性疾病个性化免疫抑制治疗。</p>
<p>这项投资将支持 Biohope 完成临床验证研究，并寻求美国监管批准，然后推动其旗舰技术 Immunobiogram®的采用，这是一种创新的体外诊断平台，帮助临床医生个性化免疫抑制治疗，减少并发症，并使移植肾脏更长时间地保持功能。</p>
<p>肾脏移植接受者需要终身服用免疫抑制药物以防止器官排斥。然而，目前的治疗方法往往依赖于试错调整，这可能导致严重的并发症，包括排斥、感染、心血管疾病、毒性和最终的移植物丧失。Biohope 的技术旨在帮助医生更精确地根据每位患者的免疫反应量身定制治疗。</p>
<p>根据 Biohope 的数据，最多有 50% 的肾脏移植接受者在 10 年内失去移植物，这突显了对更个性化的移植后护理方法的迫切需求。</p>
<p>“成功的肾脏移植并不是患者旅程的终点——而是管理药物及其副作用的终身平衡行为的开始，” 国家肾脏基金会首席执行官、肾脏移植接受者 Kevin Longino 说。“Biohope 的工作旨在帮助临床医生个性化免疫抑制治疗，减少并发症，保护移植肾脏，并最终通过帮助患者保持移植器官的功能更长时间来拯救生命。”</p>
<p>Immunobiogram®分析患者的免疫细胞如何对不同的免疫抑制药物作出反应，生成个性化的敏感性图谱，帮助临床医生优化治疗决策。Biohope 报告称，该平台已在西班牙商业化，并在多个临床研究中评估了超过 1,000 名患者。</p>
<p>“对于肾脏移植患者来说，维持适当的免疫抑制平衡是一项终身挑战，” Biohope 首席执行官 Virginia González 说。“NKF 深刻理解移植患者和临床医生面临的未满足需求。他们的支持将在我们完成临床验证、推进美国监管批准的过程中发挥重要作用，并使个性化免疫抑制治疗成为更多患者的现实。”</p>
<p>Biohope 的技术目前专注于肾脏移植，未来还在探索在自身免疫和炎症性疾病中的应用。</p>
<p>NKF 创新基金于 2021 年启动，旨在加速肾脏患者所需和应得的治疗的资金、开发和商业化。该基金投资于开发创新、以患者为中心的肾脏治疗的早期至中期公司。NKF 创新基金的长期目标是预防肾脏疾病，消除移植等待名单，并为透析患者提供更好、更安全的治疗，使他们能够过上更充实和更有生产力的生活。有关 NKF 创新基金的更多信息，请访问 kideny.org/innovationfund。</p>
<p><strong>肾脏疾病</strong></p>
<p>在美国，估计有超过 3700 万成年人患有肾脏疾病，也称为慢性肾脏疾病（CKD）——大约 90% 的人不知道自己患有此病。美国约有 1/3 的成年人面临肾脏疾病的风险。肾脏疾病的风险因素包括：糖尿病、高血压、心脏病、肥胖和家族史。黑人或非裔美国人、西班牙裔或拉丁裔、美国印第安人或阿拉斯加土著、亚裔美国人或夏威夷原住民或其他太平洋岛屿原住民的风险更高。黑人或非裔美国人患肾衰竭的可能性约为白人的四倍。西班牙裔的肾衰竭发生率约为白人的两倍。</p>
<p><strong>关于 Biohope</strong></p>
<p>Biohope 是一家专注于免疫学精准医学的生物技术公司。其旗舰产品 Immunobiogram®是一种个性化诊断平台，旨在通过测量个体对多种免疫抑制药物的免疫反应来优化肾脏移植接受者的免疫抑制治疗。Biohope 成立于 2015 年，正在推进旨在改善移植物存活率、减少并发症并支持更个性化的移植和免疫介导疾病护理的技术。了解更多信息请访问 Biohope。</p>
<p><strong>关于国家肾脏基金会</strong></p>
<p>国家肾脏基金会正在通过消除可预防的肾脏疾病、加速创新以提升患者体验的尊严，以及拆除肾脏护理、透析和移植中的结构性不平等，彻底改变拯救生命的斗争。有关 NKF 的更多信息，请访问 kideny.org。</p>
<p>来源：国家肾脏基金会</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9REM1OTE5OSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQwMTAwUFJfTkVXU19VU1BSX19fX19EQzU5MTk5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9REM1OTE5OSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQwMTAwUFJfTkVXU19VU1BSX19fX19EQzU5MTk5"/></p>

医疗业 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

标普全球医疗股指数 ETF - iShares

<p>国家肾脏基金会（NKF）已投资于 Biohope，这是一家专注于肾脏移植个性化医疗的生物技术公司。此次投资旨在支持 Biohope 的临床验证研究和其 Immunobiogram®平台的监管审批，该平台为个体患者量身定制免疫抑制治疗。这项技术旨在减少并发症并提高肾脏移植受者的移植物存活率，以应对个性化移植后护理的迫切需求。NKF 于 2021 年启动的创新基金支持创新的肾脏治疗，以改善患者的治疗效果</p>

<p>, /PRNewswire/ -- The National Kidney Foundation (NKF) announced today that its Innovation Fund has invested in Biohope, a biotechnology company developing precision diagnostics designed to personalize immunosuppressive therapy for kidney transplant recipients and autoimmune and inflammatory diseases.</p>
<div class="lb-trans"><p>/PRNewswire/ -- 国家肾脏基金会（NKF）今天宣布，其创新基金已投资于 Biohope，这是一家开发精准诊断技术的生物技术公司，旨在为肾脏移植接受者以及自身免疫和炎症性疾病个性化免疫抑制治疗。</p>
</div><p>The investment will support Biohope's efforts to complete clinical validation studies and seek U.S. regulatory approval then drive adoption of its flagship technology, Immunobiogram®, an innovative in vitro diagnostic platform that helps clinicians personalize immunosuppressive therapy, reduce complications, and keeps transplanted kidneys functioning longer.</p>
<div class="lb-trans"><p>这项投资将支持 Biohope 完成临床验证研究，并寻求美国监管批准，然后推动其旗舰技术 Immunobiogram®的采用，这是一种创新的体外诊断平台，帮助临床医生个性化免疫抑制治疗，减少并发症，并使移植肾脏更长时间地保持功能。</p>
</div><p>Kidney transplant recipients require lifelong immunosuppressive medications to prevent organ rejection. However, current treatment approaches often rely on trial-and-error adjustments that can lead to serious complications, including rejection, infection, cardiovascular disease, toxicity, and eventual graft loss. Biohope's technology is designed to help physicians tailor treatment more precisely to each patient's immune response.</p>
<div class="lb-trans"><p>肾脏移植接受者需要终身服用免疫抑制药物以防止器官排斥。然而，目前的治疗方法往往依赖于试错调整，这可能导致严重的并发症，包括排斥、感染、心血管疾病、毒性和最终的移植物丧失。Biohope 的技术旨在帮助医生更精确地根据每位患者的免疫反应量身定制治疗。</p>
</div><p>According to Biohope, up to 50% of kidney transplant recipients lose their graft within 10 years, underscoring the urgent need for more personalized approaches to post-transplant care.</p>
<div class="lb-trans"><p>根据 Biohope 的数据，最多有 50% 的肾脏移植接受者在 10 年内失去移植物，这突显了对更个性化的移植后护理方法的迫切需求。</p>
</div><p>&#34;A successful kidney transplant is not the end of the journey for patients — it is the beginning of a lifelong balancing act managing medications and their side effects,&#34; said Kevin Longino, CEO of the National Kidney Foundation and a kidney transplant recipient. &#34;Biohope's work intends to help clinicians personalize immunosuppressive therapy, reduce complications, protect transplanted kidneys, and ultimately save lives by helping patients keep their transplanted organs functioning longer.&#34;</p>
<div class="lb-trans"><p>“成功的肾脏移植并不是患者旅程的终点——而是管理药物及其副作用的终身平衡行为的开始，” 国家肾脏基金会首席执行官、肾脏移植接受者 Kevin Longino 说。“Biohope 的工作旨在帮助临床医生个性化免疫抑制治疗，减少并发症，保护移植肾脏，并最终通过帮助患者保持移植器官的功能更长时间来拯救生命。”</p>
</div><p>Immunobiogram® analyzes how a patient's immune cells respond to different immunosuppressive drugs, generating individualized sensitivity maps that can help clinicians optimize treatment decisions. Biohope reports that the platform, which is already commercially available in Spain has been evaluated in more than 1,000 patients across multiple clinical studies.</p>
<div class="lb-trans"><p>Immunobiogram®分析患者的免疫细胞如何对不同的免疫抑制药物作出反应，生成个性化的敏感性图谱，帮助临床医生优化治疗决策。Biohope 报告称，该平台已在西班牙商业化，并在多个临床研究中评估了超过 1,000 名患者。</p>
</div><p>&#34;For kidney transplant patients, maintaining the right balance of immunosuppression is a lifelong challenge,&#34; said Virginia González, CEO of Biohope. &#34;NKF has a deep understanding of the unmet needs faced by transplant patients and clinicians. Their support will be instrumental as we complete clinical validation, advance toward U.S. regulatory approval, and make personalized immunosuppressive therapy a reality for many more patients.&#34;</p>
<div class="lb-trans"><p>“对于肾脏移植患者来说，维持适当的免疫抑制平衡是一项终身挑战，” Biohope 首席执行官 Virginia González 说。“NKF 深刻理解移植患者和临床医生面临的未满足需求。他们的支持将在我们完成临床验证、推进美国监管批准的过程中发挥重要作用，并使个性化免疫抑制治疗成为更多患者的现实。”</p>
</div><p>Biohope's technology is currently focused on kidney transplantation, with future applications being explored in autoimmune and inflammatory diseases.</p>
<div class="lb-trans"><p>Biohope 的技术目前专注于肾脏移植，未来还在探索在自身免疫和炎症性疾病中的应用。</p>
</div><p>Launched in 2021, the NKF Innovation Fund works to accelerate funding, development, and commercialization of therapies that kidney patients need and deserve. The fund invests in early to mid-stage companies that are developing innovative, patient-centric kidney therapies. The long-term goals of the NKF Innovation Fund are to prevent kidney disease, eliminate the transplant waitlist, and provide better, safer treatments for dialysis patients so they can live fuller and more productive lives. For more information about the NKF Innovation Fund, please visit kidney.org/innovationfund.</p>
<div class="lb-trans"><p>NKF 创新基金于 2021 年启动，旨在加速肾脏患者所需和应得的治疗的资金、开发和商业化。该基金投资于开发创新、以患者为中心的肾脏治疗的早期至中期公司。NKF 创新基金的长期目标是预防肾脏疾病，消除移植等待名单，并为透析患者提供更好、更安全的治疗，使他们能够过上更充实和更有生产力的生活。有关 NKF 创新基金的更多信息，请访问 kideny.org/innovationfund。</p>
</div><p><strong>Kidney Disease</strong></p>
<div class="lb-trans"><p><strong>肾脏疾病</strong></p>
</div><p>In the United States, more than 37 million adults are estimated to have kidney disease, also known as chronic kidney disease (CKD)—and approximately 90 percent don't know they have it. About 1 in 3 adults in the U.S. are at risk for kidney disease. Risk factors for kidney disease include: diabetes, high blood pressure, heart disease, obesity, and family history. People of Black or African American, Hispanic or Latino, American Indian or Alaska Native, Asian American, or Native Hawaiian or Other Pacific Islander descent are at increased risk for developing the disease. Black or African American people are about four times as likely as White people to have kidney failure. Hispanics experience kidney failure at about double the rate of White people.</p>
<div class="lb-trans"><p>在美国，估计有超过 3700 万成年人患有肾脏疾病，也称为慢性肾脏疾病（CKD）——大约 90% 的人不知道自己患有此病。美国约有 1/3 的成年人面临肾脏疾病的风险。肾脏疾病的风险因素包括：糖尿病、高血压、心脏病、肥胖和家族史。黑人或非裔美国人、西班牙裔或拉丁裔、美国印第安人或阿拉斯加土著、亚裔美国人或夏威夷原住民或其他太平洋岛屿原住民的风险更高。黑人或非裔美国人患肾衰竭的可能性约为白人的四倍。西班牙裔的肾衰竭发生率约为白人的两倍。</p>
</div><p><strong>About Biohope</strong></p>
<div class="lb-trans"><p><strong>关于 Biohope</strong></p>
</div><p>Biohope is a biotechnology company focused on precision medicine in immunology. Its flagship product, Immunobiogram®, is a personalized diagnostic platform designed to optimize immunosuppressive therapy for kidney transplant recipients by measuring individual immune response to multiple immunosuppressive drugs. Founded in 2015, Biohope is advancing technologies intended to improve graft survival, reduce complications, and support more personalized care in transplantation and immune-mediated diseases. Learn more at Biohope</p>
<div class="lb-trans"><p>Biohope 是一家专注于免疫学精准医学的生物技术公司。其旗舰产品 Immunobiogram®是一种个性化诊断平台，旨在通过测量个体对多种免疫抑制药物的免疫反应来优化肾脏移植接受者的免疫抑制治疗。Biohope 成立于 2015 年，正在推进旨在改善移植物存活率、减少并发症并支持更个性化的移植和免疫介导疾病护理的技术。了解更多信息请访问 Biohope。</p>
</div><p><strong>About the National Kidney Foundation</strong></p>
<div class="lb-trans"><p><strong>关于国家肾脏基金会</strong></p>
</div><p>The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis and transplantation. For more information about NKF, visit kidney.org</p>
<div class="lb-trans"><p>国家肾脏基金会正在通过消除可预防的肾脏疾病、加速创新以提升患者体验的尊严，以及拆除肾脏护理、透析和移植中的结构性不平等，彻底改变拯救生命的斗争。有关 NKF 的更多信息，请访问 kideny.org。</p>
</div><p>SOURCE National Kidney Foundation</p>
<div class="lb-trans"><p>来源：国家肾脏基金会</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9REM1OTE5OSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQwMTAwUFJfTkVXU19VU1BSX19fX19EQzU5MTk5" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC59199&amp;Transmission_Id=202605140100PR_NEWS_USPR_____DC59199&amp;DateId=20260514"/></p>

01:00 ETNational Kidney Foundation Innovation Fund Invests in Biohope to Advance Personalized Medicine in Kidney Transplantation

prnewswire

生物科技 ETF - VanEck Vectors

医疗业 ETF - Vanguard

动态生物技术与基因组 ETF - Invesco

2 倍做空纳斯达克生物技术 ETF - ProShares

平安中证医疗创新ETF

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

2 倍做多纳斯达克生物技术 ETF - ProShares

Invesco Nasdaq Biotechnology ETF

美国制药 ETF - iShares

医药突破 ETF - ALPS

标普生物技术 3 倍做多 - Direxion

美国东部时间 01:00，国家肾脏基金会创新基金投资 Biohope，以推动肾移植领域的个性化医疗发展